EuroMAbNet: European Monoclonal Antibodies NetworkEuroMAbNet. European Monoclonal Antibodies Network homepage

Menu

Events 11th EuroMabNet Meeting (online version)

When

17th and 18th of September 2021. One full day on Friday plus half day on Saturday.

Organisers

Registration

Registration form

Registration fees (Euros)
Participants Fees
EuroMAbNet members 0 €
Academia 50 €
Industry 100 €

For further inquiries please contact EuroMAbNet secretary Celia Ramos: cmramos@srv.cnio.es

Payment instructions

We accept credit card, PayPal or bank transfer payments.

Bank account details:

Bank: Openbank
Bank Account: 0073 0100 53 0502233517
Account number (IBAN code): ES0600730100530502233517
Bank code (SWIFT/BIC code): OPENESMM
Account owner: EUROMABNET

VERY IMPORTANT: PLEASE QUOTE YOUR NAME AS REFERENCE

Registration cancellation and refund policy

No refunds will be made in case of cancellation. Substitutions are acceptable at any time but should be informed by email at cmramos@srv.cnio.es.

Preliminary Programme

Download programme in PDF format (130 KB)

SCIENTIFIC SECTION - FRIDAY, SEPTEMBER 17th

  • CHAIR: Giovanna Roncador

  • Opening and welcome remarks

  • Invited speaker: Lindy Durrant Division of Cancer and Stem Cells, Nottingham University, UK

    Fc modification to improve the avidity of mAbs and to enhance the direct killing ability of anti-glycan mabs

  • Sophia Karagiannis Translational Cancer Immunology and Immunotherapy, St. John’s Institute of Dermatology School of Basic & Medical Biosciences, King's College, UK

    IgE class antibodies for cancer immunotherapy

  • José A. Garcia Sanz and Leonor Kremer CIB-CSIC and CNB-CSIC Protein Tools Unit, Madrid, Spain

    Therapeutic potential of 92R mAb on human CCR9+ leukemias in orthotopic xenografts

  • Student short talk: Robert HarrisTranslational Cancer Immunology and Immunotherapy, St. John’s Institute of Dermatology School of Basic & Medical Biosciences, King's College, UK

    Class switched Tumour-Infiltrating B Cells Contribute to Favourable Clinical Outcomes

  • Coffee break

  • CHAIR: Sophia Karagiannis

  • Prof. Friedrich Koch-Nolte University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Nanobody transgenic mice

  • Student short talk: Martynas Simanavičius Institute of Biotechnology, Life Science Center, Vilnius University, Vilnius, Lithuania

    Monoclonal antibodies for selective capture of chemical photocaging group and light-controlled release of target proteins

  • Student short talk: Xinkai JIA University of Pécs, Department of Immunology and Biotechnology, Hungary

    Identification of a minor mouse B-cell subset with unorthodox characteristics by IBL-33 rat mAb

  • Student short talk: Larisa Yurlova ChromoTek, Germany

    What can nanobodies do better than standard secondary antibodies? Validation of recombinant Nano-Secondaries

  • LUNCH

  • CHAIR: Vanda Juranić

  • Aurelija Zvirbliene Department of Immunology and Cell Biology Institute of Biotechnology, Vilnius, Lithuania

    The activities of Vilnius University group, a new member of the EuroMabNet

  • Robero Perris Director & Professor of Anatomy and Cell Biology, Parma University

    A Reversed immunoglycomics platform for generating therapeutic antibodies against gly- canation variants of cancer-specific antigens

  • Juan Anguita Inflammation and Macrophage Plasticity Lab & Animal Facility, Biogune, Bilbao, Spain

    Development of Point-Of-Care Diagnostic tools

  • Sponsor talk: Gregor Jainta PEPperPRINT GmbH, HeidelBerg, Germany

    Epitope Mapping and Characterization on Custom Peptide Microarrays

  • Sponsor talk: Raymond Chan Bio-Techne, UK

    Antibody validation, platform and assay development for COVID-19

  • Coffee break

  • CHAIR: Berislav Lisnic

  • Ilse Hofmann GPCF Unit Antibodies, German Cancer Research Center, Heidelberg, Germany

    Success stories from the DKFZ core facility unit antibodies: IHC-compatible antibodies used in diagnostics

  • Alnabulsi Ayham Cofounder & CEO of Vertebrate Antibodies Ltd

    B-cell epitope mapping and antigenicity profiling software

  • 'El Alaoui Saïd Covalab

    CovIsoLink, a new enzymatic conjugation for the development of innovative AntibodyDrug Conjugates (ADC)

SCIENTIFIC SECTION - SATURDAY, SEPTEMBER 18th

  • CHAIR: Pierre Martineau

  • Gabriel Ayme Antibody engineering Platform, Institut Pasteur, France

    Coronabodies : nanobodies directed against the different variants of SARS-CoV-2 proteins

  • Tristan Mangeat Functional screening and targeting in cancer, IRCM INSERM, France

    Selection of environment-modulable antibodies to optimize specificity-toxicity balance of therapeutic antibodies

  • Steve Schoonooghe (VIB) VIB Nanobody Core, VUB - Cellular and Molecular Immunology

    Nanobody-based serum half-life extension of therapeutics

  • Jose Ignacio Rodriguez Barbosa Laboratory of Transplantation Immunobiology, University of Leon, Spain

    Therapeutic blockade of LIGHT (TNFSF14) interaction with HVEM and LTßR attenuates in vivo cytotoxic allogeneic responses

  • Coffee break

  • CHAIR: Friedrich Koch-Nolte

  • Student short talk: Sandra Omejec Blood Transfusion Centre of Slovenia, Centre for production of diagnostic reagents and research, Centre of Immunology and research

    Optimization of the method for generating human monoclonal antibodies from peripheral blood of vaccinated donors on the model of Hepatitis B Virus

  • Giovanna Roncador and Pablo Engel Monoclonal Antibodies Unit CNIO, Madrid and Department of Biomedical Sciences, University of Barcelona, Spain

    CD229 (Ly9) a biomarker for B cell malignancies and multiple myeloma